A gene therapy core facility is proposed to facilitate clinical trials studies. The facility will perform and oversee FDA and RAC required safety testing for patients participating in gene therapy trials at Indiana University. The core will also contain a shared vector production facility which will supply viral vector for clinical protocols. A facility capable of producing and testing retroviral and adeno-associated viral vectors will be housed in the Cancer Research Building and will occupy 1800 sq. feet of space. The laboratory is specifically designed for the production of clinical grade viral vector under Good Laboratory and Good Manufacturing Practice criteria (GLP and GMP). Clinical grade supernate will be produced by a technician with experience in GMP production and a technician with experience in retroviral vector testing. The facility will be overseen by an investigator who has successfully written Investigational New Drug (IND) applications for retroviral vectors and is currently conducting clinical trials using retroviral vectors. Funding is requested for supplies and technical personnel to perform FDA required safety testing of clinical samples obtained from patients enrolled in gene therapy trials. The laboratory will also provide support for vector production, although investigators will be required to contribute funds to cover the cost of supplies used in vector production and testing. The laboratory will play a critical role in vectors development, allowing the generation of promising vectors in a timely fashion and by providing standardized safety testing for trial participants.

Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Song, Liujiang; Kauss, M Ariel; Kopin, Etana et al. (2013) Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo. Cytotherapy 15:986-98
Jin, Qingwen; Marsh, Jon; Cornetta, Kenneth et al. (2008) Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors. J Gen Virol 89:2611-21
Case, Jamie; Horvath, Tamara L; Ballas, Christopher B et al. (2008) In vitro clonal analysis of murine pluripotent stem cells isolated from skeletal muscle and adipose stromal cells. Exp Hematol 36:224-34
Zhang, Shangming; Joseph, Guiandre; Pollok, Karen et al. (2006) G2 cell cycle arrest and cyclophilin A in lentiviral gene transfer. Mol Ther 14:546-54
Goebel, W Scott; Mark, Lawrence A; Billings, Steven D et al. (2005) Gene correction reduces cutaneous inflammation and granuloma formation in murine X-linked chronic granulomatous disease. J Invest Dermatol 125:705-10
Case, Jamie; Horvath, Tamara L; Howell, Jonathan C et al. (2005) Clonal multilineage differentiation of murine common pluripotent stem cells isolated from skeletal muscle and adipose stromal cells. Ann N Y Acad Sci 1044:183-200
Cornetta, K; Matheson, L; Ballas, C (2005) Retroviral vector production in the National Gene Vector Laboratory at Indiana University. Gene Ther 12 Suppl 1:S28-35
Broxmeyer, Hal E; Orschell, Christie M; Clapp, D Wade et al. (2005) Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201:1307-18
Kahl, Christoph A; Pollok, Karen; Haneline, Laura S et al. (2005) Lentiviral vectors pseudotyped with glycoproteins from Ross River and vesicular stomatitis viruses: variable transduction related to cell type and culture conditions. Mol Ther 11:470-82
Sastry, Lakshmi; Xu, Yi; Duffy, Lisa et al. (2005) Product-enhanced reverse transcriptase assay for replication-competent retrovirus and lentivirus detection. Hum Gene Ther 16:1227-36

Showing the most recent 10 out of 78 publications